Pages that link to "Q54061091"
Jump to navigation
Jump to search
The following pages link to Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. (Q54061091):
Displaying 50 items.
- Topotecan for ovarian cancer (Q24243056) (← links)
- Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. (Q27851478) (← links)
- Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics (Q30444706) (← links)
- A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors (Q33339062) (← links)
- Effect of topotecan infusion duration on hematologic toxicity in recurrent ovarian carcinoma (Q33342528) (← links)
- Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer (Q33346522) (← links)
- Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study (Q33357108) (← links)
- A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies (Q33357438) (← links)
- Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers (Q33362769) (← links)
- Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer (Q33364017) (← links)
- Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma (Q33367059) (← links)
- Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study (Q33369079) (← links)
- A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study (Q33374599) (← links)
- Weekly topotecan for recurrent platinum resistant ovarian cancer (Q33376847) (← links)
- Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer (Q33379246) (← links)
- Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers (Q33379265) (← links)
- Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma (Q33379831) (← links)
- Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer (Q33932032) (← links)
- Novel formulations of taxanes: a review. Old wine in a new bottle? (Q34563540) (← links)
- Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers (Q34616645) (← links)
- Epithelial ovarian cancer (Q34677827) (← links)
- Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan (Q35143044) (← links)
- Clinical experience with topotecan in relapsed ovarian cancer (Q35226240) (← links)
- Weekly topotecan in the management of ovarian cancer (Q35226263) (← links)
- Optimal sequencing in the treatment of recurrent ovarian cancer (Q35226268) (← links)
- Workshop: options for therapy in ovarian cancer (Q35226273) (← links)
- A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers (Q35671530) (← links)
- SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. (Q35840419) (← links)
- Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer (Q35968742) (← links)
- Treatment options in the management of ovarian cancer (Q36150781) (← links)
- Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan? (Q36488198) (← links)
- Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics (Q36671493) (← links)
- Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma (Q37565155) (← links)
- Palliative chemotherapy for malignant ascites secondary to ovarian cancer (Q37987902) (← links)
- Chemoresistance testing of human ovarian cancer cells and its in vitro model (Q39663833) (← links)
- MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy (Q39880558) (← links)
- The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model (Q40533881) (← links)
- A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). (Q43466435) (← links)
- Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. (Q44168595) (← links)
- Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors (Q44197097) (← links)
- Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy (Q44431298) (← links)
- A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma (Q44637217) (← links)
- A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. (Q44667134) (← links)
- Salvage therapy with topotecan in heavily pretreated ovarian cancer patients (Q46228021) (← links)
- Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown (Q47586730) (← links)
- Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. (Q53617381) (← links)
- Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. (Q53626292) (← links)
- Potential conflict between fundamental ethical principles and requirements of the oncology drug approval process: ethical conflict in drug approval (Q58665374) (← links)
- A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy (Q79256704) (← links)
- A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma (Q80332147) (← links)